October 26, 2020
1 min watch
Save
Recent advances in therapy focus on building a better anti-VEGF inhibitor
Healio spoke with Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine and Healio/OSN Board Member, about recent advances in therapy have been focused on building a better anti-VEGF inhibitor, such as products that will have longer-acting suppression and new mechanisms of action to inhibit other pathways in the first video of this series.
Click here to watch the next video in the series on anti-VEGF-related highlights from ARVO and ASRS.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Singh reports consulting for Alcon, Bausch + Lomb, Genentech, Novartis, Regeneron and Zeiss, and research grants from Aerie Pharmaceuticals, Apellis and Graybug.
Read more about